Conivaptan

CAS: 210101-16-9

Ref. 3D-FC159956

Información del producto

• Nombre: Conivaptan
• Sinónimos: Conviaptan, N-[4-[(4,5-Dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-[1,1′-Biphenyl]-2-carboxamide, Zinc 12503187, [1,1'-biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(3H)-yl)carbonyl]phenyl]-, [1,1′-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-
• CAS: 210101-16-9

Descripción

Conivaptan is a drug that has been shown to be effective in the prevention and treatment of hyponatremia. It was originally developed as an antagonist for vasopressin, a hormone that increases the amount of water excreted by the kidneys. Conivaptan prevents vasopressin from binding to its receptors and therefore reduces the effects of vasopressin on the kidney. The drug can also be used to treat congestive heart failure, cardiac arrhythmia, or chronic heart failure. The optimum concentration of conivaptan is not yet known but it has been shown to bind to receptors in experimental models with high affinity. Concentration-time curves indicate that conivaptan should be administered orally at a dose of 0.4 mg/kg every 12 hours for optimal efficacy.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 498.58 g/mol
• Fórmula: C₃₂H₂₆N₄O₂
• Pureza: Min. 95%
• Color/Forma: Powder
• InChI: InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
• Clave InChI: InChIKey=IKENVDNFQMCRTR-UHFFFAOYSA-N
• SMILES: Cc1nc2c([nH]1)CCN(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)c1ccccc1-2